Search research articles
Contact Us
Filters
Showing results (61-70 of 92) with videos related to
Page
of 10
Sort By:
Clinical Physiology and Functional Imaging
|
February 20, 2026
FDG and FAPI PET-based response evaluation to reduced-dose nivolumab in pleural mesothelioma: A case report
Morten Bentestuen, Anne H Thostrup, Weronika M Szejniuk, et al.
Seminars in Nuclear Medicine
|
June 10, 2026
The diagnostic performance and clinical value of [18F]FDG PET/CT in pleural mesothelioma - A systematic review and meta-analysis
Anne H Thostrup, Natasja U Stubbe, Mathias P Schreiner, et al.
Urology
|
August 2, 2017
Bone Scan Index Is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Newly Diagnosed Prostate Cancer: A Prospective Study
Helle D Zacho, Michael Gade, Jesper C Mortensen, et al.
Molecular and Clinical Oncology
|
July 8, 2017
<sup>68</sup>Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review
Lars J Petersen, Julie B Nielsen, Katja Dettmann, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 19, 2023
The diagnostic accuracy of radiolabeled PSMA-ligand PET for tumour staging in newly diagnosed prostate cancer patients compared to histopathology: a systematic review and meta-analysis
Farid Gossili, Anna Winther Mogensen, Tea Caroline Konnerup, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 13, 2021
Comparing the clinical performance and cost efficacy of [<sup>68</sup>Ga]Ga-PSMA-11 and [<sup>18</sup>F]PSMA-1007 in the diagnosis of recurrent prostate cancer: a Markov chain decision analysis
Ian Alberts, Clemens Mingels, Helle D Zacho, et al.
Clinical Nuclear Medicine
|
May 9, 2017
A Comprehensive Safety Evaluation of 68Ga-Labeled Ligand Prostate-Specific Membrane Antigen 11 PET/CT in Prostate Cancer: The Results of 2 Prospective, Multicenter Trials
Julie B Nielsen, Helle D Zacho, Uwe Haberkorn, et al.
Clinical Nuclear Medicine
|
June 20, 2018
68Ga-PSMA PET/CT in Patients With Biochemical Recurrence of Prostate Cancer: A Prospective, 2-Center Study
Helle D Zacho, Julie B Nielsen, Katja Dettmann, et al.
EJNMMI Research
|
January 7, 2017
Three-minute SPECT/CT is sufficient for the assessment of bone metastasis as add-on to planar bone scintigraphy: prospective head-to-head comparison to 11-min SPECT/CT
Helle D Zacho, José A Biurrun Manresa, Ramune Aleksyniene, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
May 5, 2021
Authors' reply: PSMA-PET: is the time to say goodbye to metabolic radiopharmaceuticals in prostate cancer?
Ian Alberts, Svenja Elizabeth Seide, Clemens Mingels, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 92) with videos related to
Sort By:
Page
of 10
Clinical Physiology and Functional Imaging
|
February 20, 2026
FDG and FAPI PET-based response evaluation to reduced-dose nivolumab in pleural mesothelioma: A case report
Morten Bentestuen, Anne H Thostrup, Weronika M Szejniuk, et al.
Seminars in Nuclear Medicine
|
June 10, 2026
The diagnostic performance and clinical value of [18F]FDG PET/CT in pleural mesothelioma - A systematic review and meta-analysis
Anne H Thostrup, Natasja U Stubbe, Mathias P Schreiner, et al.
Urology
|
August 2, 2017
Bone Scan Index Is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Newly Diagnosed Prostate Cancer: A Prospective Study
Helle D Zacho, Michael Gade, Jesper C Mortensen, et al.
Molecular and Clinical Oncology
|
July 8, 2017
<sup>68</sup>Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review
Lars J Petersen, Julie B Nielsen, Katja Dettmann, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 19, 2023
The diagnostic accuracy of radiolabeled PSMA-ligand PET for tumour staging in newly diagnosed prostate cancer patients compared to histopathology: a systematic review and meta-analysis
Farid Gossili, Anna Winther Mogensen, Tea Caroline Konnerup, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 13, 2021
Comparing the clinical performance and cost efficacy of [<sup>68</sup>Ga]Ga-PSMA-11 and [<sup>18</sup>F]PSMA-1007 in the diagnosis of recurrent prostate cancer: a Markov chain decision analysis
Ian Alberts, Clemens Mingels, Helle D Zacho, et al.
Clinical Nuclear Medicine
|
May 9, 2017
A Comprehensive Safety Evaluation of 68Ga-Labeled Ligand Prostate-Specific Membrane Antigen 11 PET/CT in Prostate Cancer: The Results of 2 Prospective, Multicenter Trials
Julie B Nielsen, Helle D Zacho, Uwe Haberkorn, et al.
Clinical Nuclear Medicine
|
June 20, 2018
68Ga-PSMA PET/CT in Patients With Biochemical Recurrence of Prostate Cancer: A Prospective, 2-Center Study
Helle D Zacho, Julie B Nielsen, Katja Dettmann, et al.
EJNMMI Research
|
January 7, 2017
Three-minute SPECT/CT is sufficient for the assessment of bone metastasis as add-on to planar bone scintigraphy: prospective head-to-head comparison to 11-min SPECT/CT
Helle D Zacho, José A Biurrun Manresa, Ramune Aleksyniene, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
May 5, 2021
Authors' reply: PSMA-PET: is the time to say goodbye to metabolic radiopharmaceuticals in prostate cancer?
Ian Alberts, Svenja Elizabeth Seide, Clemens Mingels, et al.
Page
of 10